Showing 4991-5000 of 7518 results for "".
- FDA Speeds Development of Hair Loss Drug Rezpegaldesleukinhttps://practicaldermatology.com/news/fda-speeds-development-of-nektars-autoimmune-hair-loss-drug/2475953/The FDA has granted Fast Track designation to the investigational biologic rezpegaldesleukin (Nektar Therapeutics) for the treatment of severe-to-very severe alopecia areata (AA) in adults and adolescents aged 12 and older who weigh at least 40 kg.
- Data Show HS Tied to Elevated Depression, Anxiety Riskhttps://practicaldermatology.com/news/data-show-hs-tied-to-elevated-depression-anxiety-risk/2475943/Patients with hidradenitis suppurativa (HS) face elevated risk of developing new-onset depression and anxiety compared with the general population, according to findings from a population-based cohort. The analysis included 1
- NPF and Boehringer Unite to Launch First GPP Awareness Dayhttps://practicaldermatology.com/news/NPF-Boehringer-Unite-Launch-First-GPP-Awareness-Day/2475890/Key Takeaways NPF and Boehringer Ingelheim launched a campaign to educate and support individuals with generalized pustular psoriasis.
- 2025 ASDS Survey: 70% of Consumers Considering Cosmetic Procedureshttps://practicaldermatology.com/news/2025-asds-survey-70-of-consumers-considering-cosmetic-procedures/2475889/Seventy percent of Americans are considering a cosmetic dermatologic procedure, trusting board-certified dermatologists as top influencers in patient decision-making, according to the 2025 Consumer Survey on Cosmetic Dermatologic Procedures by the American Society
- Analysis: Arnica’s Popularity on Social Not Supported by Data for Post-Procedure Recoveryhttps://practicaldermatology.com/news/analysis-arnicas-popularity-on-social-media-outpaces-scientific-support-for-post-procedure-recovery/2475830/Social media users and health care professionals frequently endorse Arnica montana for reducing bruising and swelling following aesthetic injectables, but a recent analysis shows scientific support for its use may be lacking.
- Multimodal "Toolkit" Enhances AI Detection of Skin Lesions: Researchershttps://practicaldermatology.com/news/multimodal-dataset-enhances-ai-detection-of-skin-lesions/2475786/A new open-access dataset, MILK10k, provides over 10,000 multimodal images to improve machine learning performance in the diagnosis of both pigmented and non-pigmented skin cancers and simulators. According to researchers publ
- ADmirable Trial: Lebrikizumab Shows Efficacy in AD Among Skin of Color Populationshttps://practicaldermatology.com/news/admirable-lebrikizumab-shows-efficacy-in-ad-among-skin-of-color-populations/2475811/Lebrikizumab significantly improved atopic dermatitis (AD) outcomes in patients with skin of color in the ADmirable phase 3b trial. The ADmirable study, and open-label, 24-week trial evaluating lebrikizumab in patients with F
- LEQSELVI™ Launches in U.S. as Oral Treatment for Severe Alopecia Areatahttps://practicaldermatology.com/news/leqselvitm-launches-in-us-as-oral-treatment-for-severe-alopecia-areata/2475680/Sun Pharmaceutical Industries Ltd. announced the U.S. commercial availability of LEQSELVI™ (deuruxolitinib), an oral Janus kinase (JAK) inhibitor indicated for the treatment of adults with severe alopecia areata, according to a press release from the manufacturer.
- Positive Early Results in Tralokinumab Trial for AD on Handshttps://practicaldermatology.com/news/Positive-Early-Results-Tralokinumab-Trial-AD-Hands/2475575/A trial evaluating tralokinumab for the treatment of adults with moderate-to-severe atopic dermatitis (AD) on the hands, who are candidates for systemic therapy, met the primary endpoint and all secondary endpoints with a statistically significant improvement in AD on the hands after 16 weeks of
- Anaysis: Linperlisib and Chidamide Safe, Effective in Advanced CTCLhttps://practicaldermatology.com/news/anaysis-linperlisib-and-chidamide-safe-effective-in-advanced-ctcl/2475518/An investigational combination of linperlisib and chidamide demonstrated clinical activity in patients with relapsed or refractory cutaneous T-cell lymphoma (CTCL), according to results from a phase 1 trial. The single-arm, n